Longitudinal Change in Cognitive Function and Medication Adherence in HIV-Infected Adults

Neuropsychology Lab, VA Greater Los Angeles Health Care System, CA 90073, USA.
AIDS and Behavior (Impact Factor: 3.49). 03/2011; 15(8):1888-94. DOI: 10.1007/s10461-011-9924-z
Source: PubMed


Neuropsychological (NP) dysfunction has been linked to poor medication adherence among HIV-infected adults. However, there is a dearth of research examining longitudinal changes in the relationship between NP status and adherence rates. We hypothesized that declines in NP functioning would be associated with a corresponding decline in medication adherence while stable NP functioning would be associated with stable or improving adherence rates. Participants included 215 HIV-infected adults who underwent cognitive testing at study entry and six months later. Compared to the NP stable group, the NP decline group showed a greater drop in adherence rates. Further analysis revealed that, beyond global NP, learning and memory was significantly associated with changes in adherence rates. These findings further support the link between cognitive functioning and medication adherence and illustrates the importance of documenting changes in cognitive abilities for identifying individuals at risk for poor adherence.

Download full-text


Available from: Steven A Castellon, Jun 20, 2014
  • Source
    • "Interestingly, the relationship between ECRs and health protective behaviors such as dietary behavior and physical activity also appears to be stronger (almost twice as strong in absolute terms; Hall and Fong 2013) than personality traits like conscientiousness that have previously been linked with health-related behaviors (Bogg and Roberts 2004). To date many investigations have implicated ECRs in the performance of health-related behaviors, via direct or indirect links (Becker et al. 2011; Ettenhofer et al. 2010; Hall et al. 2006; Hall 2012b; Hinkin et al. 2002; Insel et al. 2006; Jasinska et al. 2012; Panos et al. 2013), and some emerging literature supporting the causal status of such relationships in the dietary domain (e.g., Fregni et al. 2008; Houben and Jansen 2011). It has further been demonstrated that individual differences in ECRs have substantial implications for the ultimate health outcome: longevity. "

    Social Neuroscience and Public Health: Foundations for the Science of Chronic Disease Prevention, Edited by Peter Anthony Hall, 06/2013: pages 35-53; Springer.
  • Source
    • "In particular, cognitive efficiency or cognitive health, just like physical health, is often taken for granted until it is compromised. It can be argued that optimal cognitive functioning is needed to help promote biological health (i.e., remembering to take medication [17]), mental health (i.e., being able to exert enough cognitive energy to consciously switch attention from dwelling on negative thoughts to positive thoughts [18]), social competence (i.e., attending to details in conversation "
    [Show abstract] [Hide abstract]
    ABSTRACT: Highly active antiretroviral therapy has given the chance to those living with HIV to keep on living, allowing them the opportunity to age and perhaps age successfully. Yet, there are severe challenges to successful aging with HIV, one of which is cognitive deficits. Nearly half of those with HIV experience cognitive deficits that can interfere with everyday functioning, medical decision making, and quality of life. Given that cognitive deficits develop with more frequency and intensity with increasing age, concerns mount that as people age with HIV, they may experience more severe cognitive deficits. These concerns become especially germane given that by 2015, 50% of those with HIV will be 50 and older, and this older cohort of adults is expected to grow. As such, this paper focuses on the etiologies of such cognitive deficits within the context of cognitive reserve and neuroplasticity. From this, evidence-based and hypothetical prevention (i.e., cognitive prescriptions), rehabilitation (i.e., speed of processing training), and mitigation (i.e., spaced retrieval method) strategies are reviewed. Implications for nursing practice and research are posited.
    02/2013; 2013(1):297173. DOI:10.1155/2013/297173
  • [Show abstract] [Hide abstract]
    ABSTRACT: Currently, five nucleos(t)ide analogues (NUCs) are available for the treatment of chronic hepatitis B in the world. We examined the prevalence of hepatitis B virus (HBV) DNA and alanine aminotransferase normalization in patients receiving entecavir (ETV) and the frequency of ETV-resistant mutations during an approximately 27-month use of ETV in chronic hepatitis B patients in an urban hospital in Japan. A retrospective analysis of 81 NUC-naive chronic hepatitis B patients who received 0.5 mg of ETV daily was performed. HBV DNA was measured and sequence analysis of HBV DNA was performed in virological breakthrough patients. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA 5.0-7.0 log IU/mL group and all HBeAg-negative patients achieved serum HBV DNA negativity by 12 months. Four patients experienced virological breakthrough during ETV therapy. Two patients had no genotypic mutations, and medical interviews revealed that they had poor adherence to ETV. We found that some of the HBV virological breakthroughs during ETV treatment were related to poor adherence to medication, highlighting that clinicians should pay attention to the emergence of resistant mutants as well as adherence to ETV.
    Scandinavian Journal of Gastroenterology 05/2011; 46(9):1111-7. DOI:10.3109/00365521.2011.584898 · 2.36 Impact Factor
Show more